Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts

Chronic hepatitis C virus (HCV) infection has the greatest health impact in patients with advanced liver disease. The direct‐acting antiviral (DAA) regimen glecaprevir/pibrentasvir (G/P) is approved for treatment of HCV‐infected patients without cirrhosis and with compensated cirrhosis. However, eve...

Descripción completa

Detalles Bibliográficos
Autores principales: Feld, Jordan J., Forns, Xavier, Dylla, Douglas E., Kumada, Hiromitsu, de Ledinghen, Victor, Wei, Lai, Brown, Robert S., Flisiak, Robert, Lampertico, Pietro, Thabut, Dominique, Bondin, Mark, Tatsch, Fernando, Burroughs, Margaret, Marcinak, John, Zhang, Zhenzhen, Emmett, Amanda, Jacobson, Ira M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827821/
https://www.ncbi.nlm.nih.gov/pubmed/36036117
http://dx.doi.org/10.1111/jvh.13738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827821/
https://www.ncbi.nlm.nih.gov/pubmed/36036117
http://dx.doi.org/10.1111/jvh.13738

Ejemplares similares